SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: E_K_S who wrote (40337)11/30/2010 1:43:16 PM
From: Paul Senior  Respond to of 78714
 
EKS. Brazil: I'll peel off some more ULTR at $7. My intent with this and previous sales is to add back on assumption that stock will retreat. That doesn't seem to be happening.

Proceeds moved to average up a little on Brazil etf BRF.

finance.yahoo.com



To: E_K_S who wrote (40337)12/3/2010 10:47:28 PM
From: Paul Senior  Read Replies (1) | Respond to of 78714
 
EKS. Here's a more negative opinion on MRK relative to a positive opinion on ABT.

minyanville.com

These "pipeline" analyses -- they vary so much from analyst to analyst. I expect to read something in the next couple of months that will be entirely different from what Morningstar says here.

I'm still considering MRK as a possible buy for me.



To: E_K_S who wrote (40337)8/31/2011 4:17:48 PM
From: E_K_S  Read Replies (3) | Respond to of 78714
 
Eli Lilly & Co. (LLY)

Closed out my LLY position originally acquired 8/2009 & 4/2010. May reenter at lower prices (below $35). My drug stock positions include PFE, MRK, GSK, BMY & ABT. Out of COV earlier this year too.

LLY was looking at PFE's Pet drug subsidiary as this was a business the company was pursuing for growth. Nothing has come out of their discussions. Long term I see it as a net positive for LLY but with the stock's recent 10% move higher and no announcement regarding their Pet Drug expansion, I decided to book my profits and wait on the sidelines.

I would like to redeploy these funds back into the drug/health care sector to maintain my exposure to the industry. I am watching JnJ and AZN but neither I consider value buys at current prices.

Any other suggestions welcomed.

EKS